Patients with both resectable colorectal adenoma/carcinoma in situ by colonoscopy and rectal ACF
Conditions
Interventions
receive oral LKM512 powder 1g per day for 2 month
receive oral placebo powder per day for 2 month
Sponsors
Yokohama City Univesity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with both colorectal ACF and resectable adenoma/cancer. 2.Willingness to provide written informed consent
Exclusion criteria
Exclusion criteria: 1.History of regular use of Lactobacillous, Bifidobacterium preparation supplements. 2.History of regular use (defined as at least once per week) of NSAIDs and/or aspirin. 3.History of heart failure, renal failure, liver cirrhosis or chronic hepatic failure 4.History of familial adenomatous polyposis 5.History of hereditary non-polyposis colorectal cancer 6.History of inflammatory bowel disease 7.Pregnancy or possibility of pregnancy 8.Patients judged as inappropriate candidates for the trial by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of change of rectal ACF | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of microbiota Safety The cell-proliferative and apoptotic activities in the colorectal epithelium and adenoma/cancer | — |
Countries
Japan
Contacts
Public ContactTakuma Higurashi
Yokohama City Univesity Department of Gastroenterology and Hepatology
Outcome results
None listed